Island Pharmaceuticals Limited (ILA.AX)

0,0770 -0,0010 (-1,28%) A partir del 03:19PM AEST. Mercado abierto.

Island Pharmaceuticals Limited

697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
61 3 7036 7675
https://www.islandpharmaceuticals.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Paul Donald Richard MacLeman BVSc, D.V.M., F.A.C.I.D., GAICD, Grad Cert Eng, Gr	Executive Chairman	164,92k	N/A	1966
Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D.	MD, CEO, President & Executive Director	306,7k	N/A	N/A
Mr. Cameron Jones C.A.	Joint Company Secretary	N/A	N/A	N/A
Stephanie Vipond	Joint Company Secretary	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en AUD.

Descripción

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was incorporated in 2020 and is based in Camberwell, Australia.

Gobierno corporativo

El ISS Governance QualityScore de Island Pharmaceuticals Limited, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.